Patents Assigned to Immunex
  • Receptor activator of NF-&kgr;B
    Patent number: 6537763
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: March 25, 2003
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • H14 DNA and polypeptides
    Publication number: 20030045683
    Abstract: DNA encoding H14 polypeptides and methods for using the encoded polypeptides are disclosed.
    Type: Application
    Filed: January 25, 2002
    Publication date: March 6, 2003
    Applicant: Immunex Corporation
    Inventors: David John Cosman, Bruce Mosley
  • Receptor activator of NF-&kgr;B
    Patent number: 6528482
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: March 4, 2003
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • DNA encoding a receptor subunit for oncostatin M
    Patent number: 6524817
    Abstract: A novel polypeptide functions as the &bgr; chain of an oncostatin M receptor and is thus designated OSM-R&bgr;. Heterodimeric receptor proteins comprising OSM-R&bgr; and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: February 25, 2003
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman
  • Methods of screening for antagonists and agonists of polypeptides having kinase functions
    Publication number: 20030036051
    Abstract: The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.
    Type: Application
    Filed: December 18, 2001
    Publication date: February 20, 2003
    Applicant: Immunex Corporation
    Inventors: G. Duke Virca, Timothy A. Bird, Dirk M. Anderson, John S. Marken
  • Recombinant expression of Tek antagonists
    Patent number: 6521424
    Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization. Also provided are materials and methods for recombinant expression of Tek antagonists.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, William C. Fanslow, III
  • Antibodies directed against trail
    Patent number: 6521228
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • Type II Interleukin-1 receptors
    Patent number: 6521740
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
    Publication number: 20030027358
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridizes to defined nucleotide sequences, processes for producing polypeptides of the LIR family, and specific antibodies directed against LIR polypeptides. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Application
    Filed: May 2, 2002
    Publication date: February 6, 2003
    Applicant: Immunex Corporation
    Inventors: David J. Cosman, Dirk M. Anderson, Luis G. Borges
  • Methods for identifying compounds that alter kinase activity
    Patent number: 6514719
    Abstract: The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: February 4, 2003
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, G. Duke Virca, Unja Martin, Dirk M. Anderson
  • Site specific protein modification
    Publication number: 20030023049
    Abstract: Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of deleting at least one amino acid residue on the protein, replacing the at least one amino acid residue with an amino acid residue that does not react with polyethylene glycol, and contacting the protein with polyethylene glycol under conditions sufficient to conjugate the polyethylene glycol to the protein. This advantageous retention of a desired protein activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains free to interact with a binding partner ligand or cognate subsequent to the conjugation process.
    Type: Application
    Filed: September 12, 2002
    Publication date: January 30, 2003
    Applicant: Immunex Corporation
    Inventor: Dean K. Pettit
  • Molecules designated B7L-1
    Patent number: 6512095
    Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: January 28, 2003
    Assignee: Immunex Corp.
    Inventor: Peter R. Baum
  • Antibodies to interleukin-1 receptors
    Patent number: 6511665
    Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 28, 2003
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • DNA encoding type II IL-1 receptors
    Patent number: 6504023
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: January 7, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • ACPL polypeptides
    Publication number: 20030003542
    Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: August 2, 2002
    Publication date: January 2, 2003
    Applicant: Immunex Corporation
    Inventors: John E. Sims, Teresa L. Born
  • Method of stimulating an immune response with activated dendritic cells
    Patent number: 6497876
    Abstract: Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: December 24, 2002
    Assignee: Immunex Corp.
    Inventors: Eugene Maraskovsky, Hilary J. McKenna
  • Polynucleotides encoding cytokine designated LERK-5
    Patent number: 6492140
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: December 10, 2002
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Antibodies to the receptor protein designated 2F1
    Patent number: 6492496
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation. In addition, antibodies specific to 2F1 polypeptide are provided.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: December 10, 2002
    Assignee: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims
  • Death associated kinase containing ankyrin repeats (DAKAR)
    Patent number: 6489130
    Abstract: The invention is directed to purified and isolated novel DAKAR (death associated kinase containing ankyrin repeat) polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides and the uses of the above.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: December 3, 2002
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, G. Duke Virca
  • Testis-specific human SVPH1-8 proteinase
    Patent number: 6485956
    Abstract: The disclosure provides purified and isolated SVPH1-8 polypeptides, nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against such polypeptide, and fragmented peptides derived from these polypeptide. In addition, the disclosure provides uses of such polypeptides, fragmented peptides, antibodies and nucleic acids as well as kits containing the foregoing.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: November 26, 2002
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti